Drugs / JNJ-54179060
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-54179060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06788509 ↗ |
| Route | Oral | “will continue to receive JNJ-54179060 orally.” NCT06788509 ↗ |